Thank you for attending THSNA 2026. The virtual meeting is now closed.
Use this page to browse all contributing authors.
Presentations for Marek Demissie
Evaluating the Safety and Tolerability of Switching from Emicizumab to Fitusiran Prophylaxis in Males Aged ≥12 Years with Severe Hemophilia A, with and without Inhibitors: SWITCH Study |
Overview on Management of Breakthrough Bleeds and Major Surgeries Following Bleed Management Guidelines During the Fitusiran Clinical Program in People With Hemophilia |